Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden liver danger: new study scans cancer survivors for fatty liver disease

NCT ID NCT07280143

Recruiting now Knowledge-focused Sponsor: University of Bern Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is checking how common liver disease (MASLD) is in people who survived breast or colorectal cancer. Researchers will use painless scans and blood tests instead of a liver biopsy. The goal is to find better ways to catch liver problems early in cancer survivors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this study could lead to better, safer screening guidelines for liver disease in cancer survivors, enabling earlier detection and treatment.
What could go wrong
This is an observational study, not a treatment trial. The non-invasive methods may not be accurate enough to replace biopsy, and results may not apply to all cancer survivors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer colorectal cancer colorectal carcinoma metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER SURVIVORS COLORECTAL (COLON OR RECTAL) CANCER SURVIVORS MASLD/MASH (METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE / METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Clinical Research, University of Bern

    RECRUITING

    Bern, 3010, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.